EA200700292A1 - Полипептиды с повышенной экспрессией - Google Patents

Полипептиды с повышенной экспрессией

Info

Publication number
EA200700292A1
EA200700292A1 EA200700292A EA200700292A EA200700292A1 EA 200700292 A1 EA200700292 A1 EA 200700292A1 EA 200700292 A EA200700292 A EA 200700292A EA 200700292 A EA200700292 A EA 200700292A EA 200700292 A1 EA200700292 A1 EA 200700292A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cys2
cys1
polypeptide
cysteine
eed
Prior art date
Application number
EA200700292A
Other languages
English (en)
Other versions
EA010374B1 (ru
Inventor
Патрик Хоффманн
Силке Миттельштрасс
Енс Хеннеке
Тобиас Раум
Original Assignee
Микромет Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Микромет Аг filed Critical Микромет Аг
Publication of EA200700292A1 publication Critical patent/EA200700292A1/ru
Publication of EA010374B1 publication Critical patent/EA010374B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предлагается составной полипептид, содержащий исходный полипептид и домен, усиливающий экспрессию (EED); упомянутый EED содержит первый и второй аминокислотные остатки цистеина Cys1 и Cys2, причем Cys1 располагается ближе к N-концу молекулы составного полипептида, чем Cys2, а Cys1 и Cys2 разделены полипептидным линкером, который свободен от цистеина и пролина; определяет длину, достаточную для того, чтобы позволить Cys1 и Cys2 образовать внутримолекулярную дисульфидную связь друг с другом; имеет гибкую полипептидную конформацию, по существу, свободную от вторичной полипептидной структуры в водном растворе; причем по крайней мере один из остатков Cys1 и Cys2 дериватизируется с помощью дериватизирующего компонента.
EA200700292A 2004-07-16 2005-07-15 Полипептиды с повышенной экспрессией EA010374B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04016890 2004-07-16
PCT/EP2005/007748 WO2006008096A1 (en) 2004-07-16 2005-07-15 Expression-enhanced polypeptides

Publications (2)

Publication Number Publication Date
EA200700292A1 true EA200700292A1 (ru) 2007-06-29
EA010374B1 EA010374B1 (ru) 2008-08-29

Family

ID=35229693

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700292A EA010374B1 (ru) 2004-07-16 2005-07-15 Полипептиды с повышенной экспрессией

Country Status (12)

Country Link
US (1) US8518403B2 (ru)
EP (1) EP1769000B1 (ru)
JP (2) JP5014988B2 (ru)
KR (1) KR20070042967A (ru)
CN (1) CN101018809B (ru)
AU (1) AU2005263555B2 (ru)
CA (1) CA2570990C (ru)
EA (1) EA010374B1 (ru)
MX (1) MX2007000387A (ru)
NZ (1) NZ552745A (ru)
WO (1) WO2006008096A1 (ru)
ZA (1) ZA200610478B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
WO2007109321A2 (en) 2006-03-20 2007-09-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
CN101245110B (zh) * 2007-02-16 2010-09-15 鲁南制药集团股份有限公司 重组中性粒细胞抑制因子和水蛭原嵌合蛋白及其药物组合物
WO2009032949A2 (en) * 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
JP5951929B2 (ja) * 2007-10-03 2016-07-13 コーネル ユニヴァーシティー Ｐｓｍａ抗体を用いる増殖性障害の治療
RU2582244C2 (ru) * 2008-06-30 2016-04-20 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Функционализированные полипептиды
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
AU2009299791B2 (en) * 2008-10-01 2016-02-25 Amgen Research (Munich) Gmbh Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody
CN102171248B (zh) * 2008-10-01 2015-07-15 安进研发（慕尼黑）股份有限公司 种间特异性PSMAxCD3双特异性单链抗体
EP2398504B1 (en) * 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
SG176947A1 (en) * 2009-07-03 2012-01-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
WO2011069019A2 (en) 2009-12-02 2011-06-09 David Ho J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
US9315581B2 (en) 2009-12-23 2016-04-19 A Vipep Pty Limited Immuno-conjugates and methods for producing them
UA118950C2 (uk) 2011-04-22 2019-04-10 Аптево Рісьорч Енд Девелопмент Ллс Поліпептид, який зв'язує специфічний мембранний антиген простати та комплекс т-клітинного рецептора
EP2825553B1 (en) * 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
CN108289949B (zh) 2015-05-29 2022-04-12 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白质的使用方法
RU2765242C2 (ru) 2015-08-07 2022-01-27 Имаджинаб, Инк. Антигенсвязывающие конструкции против молекул-мишеней
AU2016326449A1 (en) 2015-09-21 2018-03-22 Aptevo Research And Development Llc CD3 binding polypeptides
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics Inc proteínas que se ligam a her2, nkg2d e cd16
JP2021512630A (ja) 2018-02-08 2021-05-20 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ受容体を標的とする抗体可変ドメイン
CN110668984B (zh) * 2019-12-03 2020-04-10 凯莱英医药集团（天津）股份有限公司 一种依特卡肽中间体及依特卡肽的合成方法
US11617767B2 (en) 2020-11-20 2023-04-04 Simcere Innovation, Inc. Armed dual CAR-T compositions and methods for cancer immunotherapy
CN117285647A (zh) * 2022-06-17 2023-12-26 南京北恒生物科技有限公司 靶向ccr8的嵌合抗原受体及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO2001004135A2 (en) * 1999-07-13 2001-01-18 The Regents Of The University Of Michigan Crosslinked dna condensate compositions and gene delivery methods
NZ522847A (en) * 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
AU6976201A (en) * 2000-06-09 2001-12-24 Us Health Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
JP2004507231A (ja) * 2000-06-15 2004-03-11 アメリカ合衆国 免疫応答を向上させるための、ｇｍ−ｃｓｆを発現する組換え非−複製性ウィルスおよびその使用
US7148321B2 (en) * 2001-03-07 2006-12-12 Emd Lexigen Research Center Corp. Expression technology for proteins containing a hybrid isotype antibody moiety
CN1195779C (zh) * 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
EP1497634A4 (en) * 2001-11-08 2007-02-07 Applied Research Systems PROTEIN KNOT
CA2707443A1 (en) * 2007-11-30 2009-06-11 Bristol-Myers Squibb Company Conjugates of anti-rg-1 antibodies

Also Published As

Publication number Publication date
AU2005263555A1 (en) 2006-01-26
MX2007000387A (es) 2007-03-28
CN101018809B (zh) 2012-07-18
EP1769000A1 (en) 2007-04-04
JP2012144552A (ja) 2012-08-02
EP1769000B1 (en) 2014-12-24
JP2008506659A (ja) 2008-03-06
AU2005263555B2 (en) 2011-01-27
ZA200610478B (en) 2008-04-30
US20090053223A1 (en) 2009-02-26
CA2570990C (en) 2014-01-21
JP5014988B2 (ja) 2012-08-29
EA010374B1 (ru) 2008-08-29
WO2006008096A1 (en) 2006-01-26
CA2570990A1 (en) 2006-01-26
KR20070042967A (ko) 2007-04-24
CN101018809A (zh) 2007-08-15
US8518403B2 (en) 2013-08-27
NZ552745A (en) 2009-01-31

Similar Documents

Publication Publication Date Title
EA200700292A1 (ru) Полипептиды с повышенной экспрессией
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
CO6251325A2 (es) Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)
AR054165A1 (es) Proteinas de union a il-6
EA200702402A1 (ru) Агенты, связывающие склеростин
EA201000002A1 (ru) Полипептид апф2
EA200800535A1 (ru) Пептиды и соединения, которые связываются с рецептором
EA201591049A1 (ru) Способы получения конъюгатов дисульфидсодержащих белков
UY30324A1 (es) Proteinas de fusion del rage, formulaciones y métodos de uso
ATE404225T1 (de) Radiofluorierte peptide
EA200300644A1 (ru) Слитые белки glp-1
CO5611157A2 (es) Compuestos glp-1 unidos a polietilenglicol
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
PE20091004A1 (es) Proteinas de union a antigenos c-fms humanos
EA200970416A1 (ru) Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и способы, относящиеся к ним
DK1423419T3 (da) Hybrid- og tandemekspression af Neisseria-proteiner
ES2531480T3 (es) Péptidos derivados de la proteína bplp humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos
BRPI0209685B8 (pt) derivado de peptídeo insulinotrópico e método para a produção de um derivado de peptídeo insulinotrópico
ATE522563T1 (de) Verzweigte polyalkylenglykole
DK1912673T3 (da) Fremgangsmåde til at binde effektor-molekyler til proteiner
BR0312491B1 (pt) processo para a telomerizaÇço de olefinas nço-cÍclicas.
PE20090225A1 (es) Proteinas de fusion que degradan el peptido beta amiloide
EA200702012A1 (ru) Пептиды механо-фактора роста и их применение
ES2464777T3 (es) Método de producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo
EA200600477A1 (ru) Пептиды и соединения, которые связываются с рецептором

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU